1	Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India
2	Seth A. Hoffman ^{1,} *, Christopher LeBoa ^{1,a} , Kashmira Date ^{2,b} , Pradeep Haldar ³ , Pauline Harvey ^{4,c} , Rahul
3	Shimpi ⁴ , Qian An ² , Chenhua Zhang ² , Niniya Jayaprasad ^{4,d} , Lily Horng ¹ , Kirsten Fagerli ² , Priyanka Borhade ⁴ ,
4	Debjit Chakraborty⁵, Sunil Bahl ⁶ , Arun Katkar⁴, Abhishek Kunwar⁴, Vijay Yewale ⁷ , Jason R. Andrews¹,
5	Pankaj Bhatnagar⁴, Shanta Dutta⁵, Stephen P. Luby¹
6	
7	¹ Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University
8	School of Medicine, Stanford, California, USA; ² Global Immunization Division, Center for Global Health,
9	Centers for Disease Control and Prevention, Atlanta, Georgia, USA; ³ Ministry of Health & Family Welfare,
10	Government of India, New Delhi, India; ⁴ World Health Organization-Country Office for India, National
11	Public Health Surveillance Project, New Delhi, India; ⁵ National Institute of Cholera and Enteric Diseases,
12	Indian Council of Medical Research, Kolkata, India; ⁶ World Health Organization South-East Asia Regional
13	Office, New Delhi, India; ⁷ Dr. Yewale Multispecialty Hospital for Children, Navi Mumbai, India
14	^a Current affiliation: Division of Environmental Health Sciences, School of Public Health, University of
15	California, Berkeley, California, USA; ^b Current affiliation: Johnson & Johnson Global Public Health, New
16	Brunswick, New Jersey, USA; ^c Current affiliation: U.S. Centers for Disease Control and Prevention,
17	Gaborone, Botswana; ^d World Health Organization, India Hypertension Control Initiative, New Delhi,
18	India
10	
19	Keywords: typhoid fever, Salmonella Typhi, vaccines, global health, India
20	
21	Running Title: Typhoid Vaccine Campaign Effectiveness
22	

23 *Corresponding Author:

- 24 Seth A. Hoffman, M.D.
- 25 Division of Infectious Diseases & Geographic Medicine, Stanford University School of Medicine
- 26 300 Pasteur Drive, Stanford, CA 94305 USA
- 27 Lane Building, 134
- 28 Tel: +1-650-725-8338 | Fax: +1-650-498-9876
- 29 Email: <u>sethhoffman@stanford.edu</u>
- 30
- 31 Alternate corresponding author:
- 32 Stephen P. Luby, M.D.
- 33 Stanford University
- 34 Yang and Yamazaki Environment and Energy Building
- 35 473 Via Ortega, Stanford, CA 94305 USA
- 36 Tel: +1-650-723-4129 | Fax: +1-650-725-3402
- 37 Email: sluby@stanford.edu
- 38
- 39 **40 Word Summary:** In 2018, the Navi Mumbai Municipal Corporation conducted a typhoid conjugate
- 40 vaccine campaign in half of its communities. Utilizing a test-negative design, we estimate that this
- 41 campaign reduced typhoid risk by 56% (25-74%) in vaccinated communities compared to non-campaign
- 42 communities.
- 43
- 44
- 45
- 46

47 ABSTRACT

48	Background: The WHO recommends vaccines for prevention and control of typhoid fever, especially
49	where antimicrobial-resistant typhoid circulates. In 2018 the Navi Mumbai Municipal Corporation
50	(NMMC), implemented a TCV campaign. The campaign targeted all children aged 9-months through 14-
51	years within NMMC boundaries (~320,000 children) over 2 vaccination phases. The phase 1 campaign
52	occurred from July 14-August 25, 2018 (71% coverage, ~113,420 children). We evaluated the campaign's
53	programmatic effectiveness in reducing typhoid cases at the community level.
54	Methods: We established prospective, blood culture-based surveillance at 6 hospitals in Navi Mumbai,
55	offering blood cultures to children presenting with fever for at least 3 days. We employed a cluster-
56	randomized test-negative design to estimate the effectiveness of the vaccination campaign on pediatric
57	typhoid cases. We matched culture-confirmed typhoid cases with up to 3 culture-negative controls by
58	age and date of blood culture and assessed community vaccine campaign phase as an exposure using
59	conditional logistic regression.
60	Results: Between September 1, 2018–March 31, 2021, we identified 81 typhoid cases and matched
61	these with 238 controls. Cases were 0.44 times as likely to live in vaccine campaign communities
62	(campaign effectiveness, 56%, 95%CI: 25%-74%, p=0.002). Cases ≥ 5-years-old were 0.37 times as likely
63	(95% CI: 0.19-0.70; p-value = 0.002) and cases during the first year of surveillance were 0.30 times as
64	likely (95% CI: 0.14-0.64; p-value = 0.002) to live in vaccine campaign communities.
65	Conclusions: Our findings support the use of TCV mass vaccination campaigns as effective population-
66	based tools to combat typhoid fever.
67	
68	
69	
70	
71	

72 INTRODUCTION

73

74	Typhoid fever, caused by Salmonella enterica subspecies enterica serovar Typhi (S. Typhi),
75	remains the cause of a significant burden of disease, with an estimated over 11 million cases and
76	116,000 deaths in 2017, the majority of which occurred in children under 15 years of age [1]. In the mid-
77	20 th century typhoid fever mortality dropped significantly, from upwards of 12% in the pre-antibiotic era
78	[2], to approximately one percent in most areas after the introduction of effective antibiotics [3, 4].
79	Unfortunately, antimicrobial-resistant S. Typhi is on the rise, especially in Asia [5, 6], and is associated
80	with increased severity of disease [7-9].
81	In conjunction with water, sanitation, and hygiene (WASH) interventions, the World Health
82	Organization (WHO) recommends vaccines as an important tool in typhoid prevention and control [10].
83	The WHO prequalified the first typhoid conjugate vaccine (TCV), Typbar-TCV® (Bharat Biotech
84	International Limited, India), which comprises the Vi polysaccharide conjugated to tetanus toxoid, in
85	December 2017 for use in children as young as 6 months old [10]. A second TCV (TYPHIBEV [®] , Biological
86	E. Limited, India) was prequalified in December 2020 [11]. Earlier typhoid vaccines, Ty21a and the
87	unconjugated Vi polysaccharide (ViPS) vaccine, are not recommend for infants and the ViPS vaccine is
88	not as immunogenic as TCVs [10]. In multiple studies, including randomized controlled trials, ranging
89	from infants to adults, TCVs have shown 79-95% efficacy in preventing typhoid fever [12-18], and earlier
90	analysis from this project measured a vaccine effectiveness of 82% in our sampled population [19].
91	Additionally, TCV can safely be co-administered with other routine vaccines without immune
92	interference or increased adverse events [20], making it ideal for inclusion in a country's routine
93	immunization schedule.
94	Navi Mumbai, India is an urban municipality outside of Mumbai administered by the Navi
95	Mumbai Municipal Corporation (NMMC). Prior observations suggested a high burden of typhoid in

96 children [21]. In 2018, the NMMC implemented the first phase of a public-sector pediatric TCV campaign

97	[22]. The campaign targeted all children aged 9-months through 14-years living within NMMC
98	boundaries (~320,000 children) over the course of 2 vaccination phases (each ~160,000 children). The
99	selection of areas to include in the two phases of the campaign were initially developed as a single step
100	wedge design randomized control trial in collaboration with NMMC. The first phase of the TCV mass
101	vaccination campaign occurred over the course of 6 weeks between 14 July and 25 August 2018, and
102	reached an estimated 113,420 children (71% of the target population); each child received one dose of
103	Typbar-TCV [®] . At the time of vaccination, each family received a TCV vaccination card to keep as a part of
104	their medical record. The second, delayed vaccination campaign was planned for 2020, but was
105	postponed due to the COVID-19 pandemic and has not yet been conducted. The first confirmed case of
106	COVID-19 was reported in India on January 30, 2020 [23] and a subsequent countrywide lockdown
107	started on March 25, 2020 .
108	While previous randomized clinical trial data provide safety and efficacy data, only in Pakistan
109	has TCV effectiveness been evaluated in a public sector, outbreak setting [15]. Our study provides the
110	first evaluation of a public sector mass vaccination campaign using TCV in a non-outbreak setting. This
111	information may be useful to key stakeholders and policymakers as decisions are made on whether to
112	introduce TCV into routine immunization programs through immunization campaigns in S. Typhi-
113	endemic countries.
114	
115	METHODS

116 Setting

NMMC's administrative boundaries are divided into 22 areas of approximately even population
 size, demarcated by the catchment areas of the city's 22 Urban Health Posts (UHPs). In conjunction with
 NMMC, we stratified areas based on proportion of the population living in slums (stratum 1, <10%;
 stratum 2, 10%-70%; and stratum 3, >70%) [22], and randomly assigned areas either to vaccine

121 campaign communities, which underwent the mass vaccination campaign in 2018, or delayed vaccine

122 campaign communities, which were to be included in the second phase of the vaccination campaign

123 (Figure 1). Children aged 9-months through 14-years were eligible for the vaccination campaign,

124 amounting to an estimated 320,000 children within the NMMC administrative boundaries, and an

125 estimated 160,000 children targeted for immunization in the first phase of the campaign.

126 Design

127 Original design and statistical analysis plan

128 We planned to estimate the incidence of blood culture-confirmed typhoid among children 129 eligible to receive the vaccine in the vaccine campaign communities and compare this to the delayed 130 campaign communities (https://clinicaltrials.gov/ct2/show/NCT03554213), following a single step 131 wedge design. We intended to deploy hybrid surveillance that adjusted the crude typhoid fever 132 incidence for healthcare utilization [24], utilizing prospective, blood culture-based surveillance at 6 133 hospitals and a continuous community survey. The COVID-19 pandemic radically altered healthcare 134 seeking behavior in Navi Mumbai and necessitated the suspension of the continuous community survey 135 to minimize risk to fieldworkers. But the healthcare facility blood culture surveillance continued 136 (September 1, 2018 through March 31, 2021) providing community-level blood culture data. 137 138 Revised design and statistical analysis plan

139To evaluate the effectiveness of the mass vaccination campaign in the setting of radically altered140and reduced healthcare seeking, we implemented a test-negative case-control design [25]. Among141pediatric patients presenting with a febrile illness to affiliated healthcare sites, we identified cases as142being blood culture positive for *S*. Typhi and controls as being blood culture negative for *S*. Typhi, and

we then examined home address in a vaccine campaign community or a delayed campaign communityas the exposure of interest.

145

146 Inclusion Criteria

147 We included children within the age range of eligibility for the vaccination campaign (9-months

- 148 through 14-years), and through 16-years to account for aging during the follow up period, who
- presented or were sent to a hospital sentinel site with a febrile illness (>3 days of fever within the past 7
- 150 days without upper respiratory tract symptoms and/or vesicular rash). The hospital sites were D.Y. Patil
- 151 Medical College and Hospital, Nerul; Dr. Yewale Multispecialty Hospital for Children, Vashi; Mahatma
- 152 Gandhi Memorial (MGM) New Bombay Hospital, Vashi; Mathadi Hospital Trust, Koparkharaine; NMMC
- 153 General Hospital, First Referral Unit (FRU), Vashi; and Rajmata Jijau Hospital, NMMC, Airoli. We offered
- 154 free blood culture to all participants who met the inclusion criteria. Participants were included for 33
- 155 months (September 1, 2018 March 31, 2021).

156 Exclusion Criteria

Participants were excluded if no result was recorded for their blood culture or if they did not
have a place of residence listed or listed a location outside of NMMC boundaries.

159 Data Analysis

160 We matched each case with up to 3 controls on age (+/- 12 months) and time of enrollment (+/-161 28 days) to account for age-related differences in typhoid incidence [1, 26, 27] and the seasonality of

typhoid fever in the region [28]. We attempted to match on shorter time intervals of enrollment, but
these failed to match all cases (R MatchIt Package, R version 4.0.4).

We performed conditional logistic regression (clogit function from R "survival" package, R version 4.0.4) to estimate the odds that a blood culture-positive *S*. Typhi case resided in the vaccine campaign communities versus the delayed vaccine campaign communities. We adjusted the model for participant sex and education group (whether respondent has more than primary school education or not). Programmatic campaign effectiveness was calculated as (1 – Odds Ratio) x 100.

169 We performed stratified analyses by participant age group (<5 years of age versus ≥5 years of 170 age), to assess age-specific effectiveness of the vaccine, and by time since vaccine campaign (\leq 365 days 171 [September 1, 2018 – August 31, 2019] versus > 365 days [September 1, 2019 – March 31, 2021] since 172 phase 1 of the campaign) to evaluate any differences in effectiveness between the first and second-third 173 years after the campaign. These stratified analyses were both tested for the significance of the 174 difference by interaction, as calculated by an ANOVA test for the null versus an interaction model, 175 where the interaction terms were "(study community)*(age strata)" in the age stratified analysis and 176 (study community)*(time since vaccine campaign strata)" in the time since vaccine campaign stratified 177 analysis, where study community is defined by vaccine campaign communities versus delayed vaccine 178 campaign communities.

179 Ethics Statement

We obtained written informed consent from adult caregivers and verbal assent from pediatric
 participants aged >12 years. The study protocol was approved by MGM New Bombay Hospital IRB,
 Vashi, India; Institutional Ethics Committee, Indian Council of Medical Research – National Institute of

183 Cholera and Enteric Diseases (No. A-1/2020-IEC); WHO Research Ethics Review Committee

184 (ERC.0002923); and Stanford University IRB (IRB-39627).

185

186 **RESULTS**

187	During September 1, 2018 – March 31, 2021 (33 months), we enrolled 2,953 participants who
188	met the fever definition (Figure 2). There were a total of 81 blood-culture positive cases of typhoid.
189	After matching on date of test (+/- 28 days) and age (+/- 12 months), we included 319 participants in our
190	analysis (Table 1, Figure 1). Among the 81 blood culture-positive cases of S.Typhi, 36 were from the
191	vaccine campaign communities and 45 were from the delayed vaccine campaign communities. There
192	were 238 blood-culture negative controls, 153 from the vaccine campaign communities and 85 from the
193	delayed vaccine campaign communities. The mean age of the cases was 6.9 years and the matched
194	controls 6.8 years old. Females represented 40% of cases and 47% of matched controls.
195	The unadjusted odds ratio (OR) that culture-confirmed typhoid cases resided in the vaccine
196	campaign communities versus in the delayed vaccine campaign communities was 0.44 (95% CI: 0.27-
197	0.74; p-value = 0.002). The adjusted odds ratio (aOR) was 0.44 (95% CI: 0.26-0.75; p-value = 0.003),
198	indicating that the effectiveness of the mass vaccination campaign was 56% (95% CI: 25-74%) in the
199	vaccine campaign communities (Table 2).
200	When stratified by participant age group (< 5 years of age versus \geq 5 years of age), amongst the
201	under 5 years participants, cases were 0.70 times as likely to live in vaccine campaign communities
202	compared with delayed vaccine campaign communities (campaign effectiveness, 30%, 95% CI: -110-76;
203	p-value = 0.5), while cases aged 5 years and older were 0.37 times as likely to live in vaccine campaign
204	communities (campaign effectiveness, 63%, 95% CI: 30-81; p-value = 0.002). When stratified by time
205	since campaign (≤ 365 days versus > 365 days since campaign), cases occurring within the first year after

206	the campaign were 0.30 times as likely to live in vaccine campaign communities (campaign
207	effectiveness, 70%, 95% CI: 36-86; p-value = 0.002), while cases identified during the second-third year
208	after the campaign were 0.75 times as likely to live in vaccine campaign communities (campaign
209	effectiveness, 25%, 95% CI: -70-67; p-value = 0.5).
210	
211	DISCUSSION
212	The TCV comparison excession fully upperiod on estimated 112,420 shildren in Coupelys Turksid
212	The TCV campaign successfully vaccinated an estimated 113,420 children in 6 weeks. Typhoid
213	fever cases were 56% less likely to reside in vaccine campaign communities than in delayed vaccine
214	campaign communities. When stratified by age, older case-patients (>5 years old) were 63% less likely to
215	reside in vaccine campaign communities than delayed vaccine campaign communities, but this
216	difference was not significant when tested for the significance of the difference by interaction.
217	Additionally, when stratified by time since vaccine campaign surveillance, typhoid fever cases were 70%
218	less likely to live in the vaccine campaign communities during the first year of surveillance, but this
219	difference was also not significant when tested for the significance of the difference by interaction.
220	The overall programmatic effectiveness of the vaccination campaign on the reduction of typhoid
220	
221	in the intervention community was consistent with 71% estimated vaccine coverage of an 82% effective
222	vaccine. Our crude and adjusted overall campaign effect odds ratios were similar, indicating that
223	adjustment for participant sex and respondent education had little impact, and these variables were
224	unlikely to be strong confounders.
225	
225	To minimize risk to project fieldworkers from the COVID-19 pandemic, we halted the continuous
226	community survey. Since the original study design and statistical analysis plan did not allow for this
227	significant impact on data collection, and given the effect of the marked change in healthcare utilization
228	due to the COVID-19 pandemic, we could not follow the prespecified study design. Instead, utilizing the

229	available blood culture data, we employed a test-negative design to analyze our results [29, 30]. This
230	allowed us to evaluate the overall impact of the vaccine campaign on the reduction of typhoid cases
231	between the intervention communities versus the delayed vaccine campaign communities. This study
232	design, modeled off the popular test-negative design used in influenza [31], rotavirus [32], and COVID-
233	19 [33, 34] vaccine effectiveness studies, has been shown to be concordant with vaccine effectiveness
234	results from randomized controlled trials [25, 32]. The cluster randomized test-negative design has also
235	been utilized in the evaluation of dengue control interventions [35]. Recently, the WHO issued guidance
236	recommending the use of the test-negative design for COVID-19 vaccine effectiveness studies due to
237	logistical ease and reduction of health utilization bias [33, 34].

238 In addition to the unpredictable impact of the COVID-19 pandemic, this study is limited by 239 utilizing S. Typhi blood culture as the outcome measure for test-positive cases versus test-negative 240 controls. Blood culture sensitivity in detecting S. Typhi infection is estimated to be between 55-65% [1, 241 36] and is dependent on the blood volume collected [36], for which we do not have data. As such, blood 242 culture positivity as an outcome measure may result in underreporting of test-positive cases and loss of 243 statistical power, but this would be expected to affect both vaccine campaign and delayed vaccine 244 campaign communities and so would not bias the estimate of campaign effectiveness. For now, blood 245 culture remains the standard outcome utilized by evaluations of interventions to combat S. Typhi 246 infection in controlled trials and public health programs, and S. Typhi surveillance [1, 5, 6, 9, 13-15, 17, 247 18].

There are a number of descriptions in the literature of programmatic or outbreak implementation of typhoid vaccines [15, 37-39]. However, formal assessment is limited and many lack a systematically evaluated population control group, limiting generalizability [15, 37-39]. Our results represent a metropolitan introduction of typhoid vaccine in which we systematically evaluated the

overall campaign effectiveness with control communities that had not yet undergone a TCV
immunization campaign. As compared to previous generation typhoid vaccines, unconjugated Vi
polysaccharide and Ty21a, TCVs induce consistently higher levels of protective efficacy and are indicated
for use in younger children [10]. TCVs provide more durable immune responses than do unconjugated Vi
polysaccharide vaccine, and are expected to have longer durations of protection than prior generation
typhoid vaccines [10, 16]. This study provides further evidence that TCVs are effective when rolled out in
the form of a municipal program.

259 Although the campaign did reduce typhoid, some children who lived in the intervention 260 community still developed typhoid, even some of those children who were vaccinated [19]. Effective 261 communication to stakeholders and policymakers should include the caveat that while programmatic 262 implementation of TCV in children and adolescents will reduce typhoid incidence, it is not likely to 263 interrupt all transmission and eliminate the disease for several reasons [14]. First, although highly 264 effective, typhoid vaccines are not 100% effective, as has been reported from individually randomized 265 trials [12-18]. Second, adults who are susceptible to typhoid, are not usually included in typhoid 266 immunization campaigns or programs. These adults sometimes develop typhoid fever and transmit S. 267 Typhi. Even the targeted age groups are unlikely to be fully reached by vaccine campaigns – in this study 268 vaccine coverage was an estimated 71%. Finally, vaccination will not cure S. Typhi chronic carriers, who 269 will remain a reservoir for future transmission. Thus, public health planners should be prepared to 270 communicate that TCV reduces but does not eliminate risk, and increased attention to providing food 271 and drinking water not contaminated with feces will be important to reduce typhoid-associated 272 morbidity and mortality.

Our findings support the use of TCV mass vaccination campaigns as an effective population based tool to reduce the pediatric public health burden of typhoid fever, as part of the introduction of

275	TCV into routine immunization programs. This evaluation adds to the body of research supporting TCV
276	campaigns by demonstrating these campaigns can be effective at the population level, while prior
277	modeling suggests they may be highly cost-effective [40]. Additionally, our experience is in the setting of
278	atypical population healthcare utilization or low reported typhoid incidence, the test-negative design is
279	useful in estimating programmatic campaign effectiveness. Our data adds to the growing evidence that
280	stakeholders can use to support decisions on TCV introduction to reduce the burden of typhoid fever.
281	
282	FUNDING
283	This work was supported by Bill and Melinda Gates Foundation Grant #OPP1169264 (PI: Prof. Stephen P.
284	Luby).
285	
286	ACKNOWLEDGEMENTS
287	We thank the following organizations and individuals for their contributions to this evaluation: the Navi
288	Mumbai Municipal Corporation leadership and staff, the Government of India Ministry of Health and
289	Family Welfare Universal Immunization Program, State of Maharashtra Department of Public Health and
290	Family Welfare, Indian Academy of Pediatrics Navi Mumbai Chapter, Bharat Biotech International
291	Limited, the Indian Council of Medical Research, WHO-India National Public Health Surveillance Project,
292	the Navi Mumbai Municipal Corporation Hospital (Dr. Savita Daruwalla), D.Y. Patil Medical College and

293 Hospital (Dr. Rajesh Rai, Dr. Keertana Shetty), Mathadi Trust Hospital (Dr. Divya Warrier), MGM New

- 294 Bombay Hospital Vashi (Dr. Jeetendra Gavhane, Dr. Shalini Yadav), Dr. Yewale Multi-Specialty Hospital
- for Children (Dr. Dhanya Dharmapalan), Grant Government Medical College (Dr. Nilma Hirani), Dr.
- 296 Joshi's Central Clinical Microbiology Laboratory, Vashi (Dr. Shrikrishna Joshi), Rajmata Jijau Hospital,

- 297 NMMC, Airoli (Dr. Varsha Rathod), and the Centers for Disease Control and Prevention, Atlanta, Georgia
- 298 (Dr. Kathleen Wannemuehler, Benjamin Nygren, and Matt Mikoleit).

299 **DISCLAIMER**

- 300 The findings and conclusions in this report are those of the authors and do not necessarily represent the
- 301 official position, policies, or views of the United States Centers for Disease Control and Prevention, or
- 302 the World Health Organization.

303	POTENTIAL CONFLICTS OF INTEREST

- 304 All authors report no conflicts of interest
- 305
- 306 **REFERENCES**
- 307
- GBD 2017 Typhoid and Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis **2019**; 19(4): 369-81.
- Woodward TE, Smadel JE. Management of Typhoid Fever and Its Complications. Ann Intern Med
 1964; 60(1): 144-57.
- 3133.Marmion DE. The treatment of typhoid fever with chloramphenicol; a clinical study of 330 cases314of enteric fever treated in Egypt. Trans R Soc Trop Med Hyg **1952**; 46(6): 619-38.
- 3154.Woodward TE, Smadel JE, Parker RT, Wisseman CL, Jr. Treatment of typhoid fever with316antibiotics. Ann N Y Acad Sci 1952; 55(6): 1043-55.
- Qamar FN, Yousafzai MT, Dehraj IF, et al. Antimicrobial Resistance in Typhoidal Salmonella:
 Surveillance for Enteric Fever in Asia Project, 2016–2019. Clin Infect Dis 2020;
 71(Supplement_3): S276-S84.

320 321	6.	Samajpati S, Pragasam AK, Mandal S, Balaji V, Dutta S. Emergence of ceftriaxone resistant Salmonella enterica serovar Typhi in Eastern India. Infect Genet Evol 2021 : 105093.
322 323	7.	Bhutta ZA. Impact of age and drug resistance on mortality in typhoid fever. Arch Dis Child 1996 ; 75(3): 214-7.
324 325	8.	Walia M, Gaind R, Mehta R, Paul P, Aggarwal P, Kalaivani M. Current perspectives of enteric fever: a hospital-based study from India. Ann Trop Paediatr 2005 ; 25(3): 161-74.
326 327 328	9.	Longley AT, Hemlock C, Date K, et al. Illness Severity and Outcomes Among Enteric Fever Cases From Bangladesh, Nepal, and Pakistan: Data From the Surveillance for Enteric Fever in Asia Project, 2016–2019. Clin Infect Dis 2020 ; 71(Supplement_3): S222-S31.
329 330	10.	WHO. Typhoid vaccines: WHO position paper, March 2018 - Recommendations. Vaccine 2019 ; 37(2): 214-6.
331 332	11.	Birkhold M, Mwisongo A, Pollard AJ, Neuzil KM. Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas. J Infect Dis 2021 ; 224(12 Suppl 2): S781-s7.
333 334	12.	Lin FY, Ho VA, Khiem HB, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to- five-year-old children. N Engl J Med 2001 ; 344(17): 1263-9.
335 336	13.	Shakya M, Colin-Jones R, Theiss-Nyland K, et al. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. N Engl J Med 2019 ; 381(23): 2209-18.
337 338 339	14.	Qadri F, Khanam F, Liu X, et al. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet 2021 ; 398(10301): 675-84.
340 341 342	15.	Yousafzai MT, Karim S, Qureshi S, et al. Effectiveness of typhoid conjugate vaccine against culture-confirmed Salmonella enterica serotype Typhi in an extensively drug-resistant outbreak setting of Hyderabad, Pakistan: a cohort study. Lancet Glob Health 2021 ; 9(8): e1154-e62.
343 344 345	16.	Vadrevu KM, Raju D, Rani S, et al. Persisting antibody responses to Vi polysaccharide-tetanus toxoid conjugate (Typbar TCV [®]) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination. Vaccine 2021 ; 39(45): 6682-90.
346 347	17.	Patel PD, Patel P, Liang Y, et al. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. N Engl J Med 2021 ; 385(12): 1104-15.

348 349	18.	Shakya M, Voysey M, Theiss-Nyland K, et al. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health 2021 ; 9(11): e1561-e8.
350 351 352	19.	Date K, Harvey P, Bhatnagar P, et al. Field effectiveness of a typhoid conjugate vaccine — Navi Mumbai (India), 2018-2020. American Society of Tropical Medicine and Hygiene 2020 National Meeting. Arlington, VA, 2020 .
353 354 355	20.	Sirima SB, Ouedraogo A, Barry N, et al. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. Int J Infect Dis 2021 ; 102: 517-23.
356 357 358	21.	Gavhane J, Yewale V, Weekey P, Dhanya, Warrior D. Enteric Fever in children from Navi Mumbai — Clinical Profile, Hematological features, Sensitivity Patterns and Response to Antimicrobials. Pediatr Infect Dis 2010 ; 2(1): 5-9.
359 360 361	22.	Date K, Shimpi R, Luby S, et al. Decision Making and Implementation of the First Public Sector Introduction of Typhoid Conjugate Vaccine—Navi Mumbai, India, 2018. Clin Infect Dis 2020 ; 71(Supplement_2): S172-S8.
362 363	23.	Andrews MA, Areekal B, Rajesh KR, et al. First confirmed case of COVID-19 infection in India: A case report. Indian J Med Res 2020 ; 151(5): 490-2.
364 365 366	24.	Andrews JR, Barkume C, Yu AT, et al. Integrating Facility-Based Surveillance With Healthcare Utilization Surveys to Estimate Enteric Fever Incidence: Methods and Challenges. J Infect Dis 2018 ; 218(suppl_4): S268-s76.
367 368 369	25.	De Serres G, Skowronski DM, Wu XW, Ambrose CS. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013 ; 18(37).
370 371	26.	Sinha A, Sazawal S, Kumar R, et al. Typhoid fever in children aged less than 5 years. Lancet 1999 ; 354(9180): 734-7.
372 373 374	27.	Walia M, Gaind R, Paul P, Mehta R, Aggarwal P, Kalaivani M. Age-related clinical and microbiological characteristics of enteric fever in India. Trans R Soc Trop Med Hyg 2006 ; 100(10): 942-8.
375 376	28.	Saad NJ, Lynch VD, Antillón M, Yang C, Crump JA, Pitzer VE. Seasonal dynamics of typhoid and paratyphoid fever. Sci Rep 2018 ; 8(1): 6870.

377 378 379	29.	Anders KL, Cutcher Z, Kleinschmidt I, et al. Cluster-Randomized Test-Negative Design Trials: A Novel and Efficient Method to Assess the Efficacy of Community-Level Dengue Interventions. Am J Epidemiol 2018 ; 187(9): 2021-8.
380 381	30.	Jewell NP, Dufault S, Cutcher Z, Simmons CP, Anders KL. Analysis of cluster-randomized test- negative designs: cluster-level methods. Biostatistics 2019 ; 20(2): 332-46.
382 383	31.	Jackson ML, Chung JR, Jackson LA, et al. Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season. N Engl J Med 2017 ; 377(6): 534-43.
384 385 386	32.	Schwartz LM, Halloran ME, Rowhani-Rahbar A, Neuzil KM, Victor JC. Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. Vaccine 2017 ; 35(1): 184-90.
387 388	33.	World Health Organization. Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021. Geneva: World Health Organization, 2021 2021.
389 390 391	34.	Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization. Vaccine 2021 ; 39(30): 4013-24.
392 393	35.	Utarini A, Indriani C, Ahmad RA, et al. Efficacy of Wolbachia-Infected Mosquito Deployments for the Control of Dengue. N Engl J Med 2021 ; 384(23): 2177-86.
394 395 396	36.	Mogasale V, Ramani E, Mogasale VV, Park J. What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review. Ann Clin Microbiol Antimicrob 2016 ; 15(1): 32.
397 398 399	37.	Yang HH, Kilgore PE, Yang LH, et al. An outbreak of typhoid fever, Xing-An County, People's Republic of China, 1999: estimation of the field effectiveness of Vi polysaccharide typhoid vaccine. J Infect Dis 2001 ; 183(12): 1775-80.
400 401	38.	Khan MI, Ochiai RL, Clemens JD. Population impact of Vi capsular polysaccharide vaccine. Expert Rev Vaccines 2010 ; 9(5): 485-96.
402 403	39.	Nga TVT, Duy PT, Lan NPH, Chau NVV, Baker S. The Control of Typhoid Fever in Vietnam. Am J Trop Med Hyg 2018 ; 99(3_Suppl): 72-8.

- 40440.Ryckman T, Karthikeyan AS, Kumar D, et al. Comparison of Strategies for Typhoid Conjugate405Vaccine Introduction in India: A Cost-Effectiveness Modeling Study. J Infect Dis 2021;406224(Supplement_5): S612-S24.
- 407

TABLES

410 Table 1: Demographic characteristics of child participants and adult respondents

	Blood-culture positive cases (N=81)	Blood-culture negative controls (N=238)	P- value
Child Age			
Mean (SD)	6.85 (3.54)	6.77 (3.54)	0.9
Median [Min, Max]	7.00 [1.00, 15.0]	7.00 [1.00, 15.0]	
Child Gender			
Male	49 (60.5%)	127 (53.4%)	0.3
Female	32 (39.5%)	111 (46.6%)	
Adult Respondent Gender			
Male	38 (46.9%)	122 (51.3%)	0.5
Female	42 (51.9%)	113 (47.5%)	
Missing	1 (1.2%)	3 (1.3%)	
Adult Respondent Age			
Mean (SD)	34.9 (7.43)	34.6 (8.66)	0.7
Median [Min, Max]	35.0 [19.0, 59.0]	34.0 [18.0, 85.0]	
Missing	0 (0%)	1 (0.4%)	
Adult Respondent Education Level			
Primary school certificate (through Grade 4) or less	6 (7.4%)	32 (13.4%)	0.1
Middle school certificate (Grade 5 - 10)	35 (43.2%)	112 (47.1%)	
High school certificate (Grade 11 - 12)	14 (17.3%)	45 (18.9%)	
Bachelors degree or greater	25 (30.9%)	49 (20.6%)	
Don't know or refused	1 (1.2%)	0 (0%)	

420 Table 2. Overall and Stratified Campaign Effectiveness

	Odds Ratio	Campaign Effectiveness (%)	P-value
Overall campaign	0.44 (0.26, 0.75)	56% (25, 74)	0.003
effectiveness			
Stratified by age			
< 5 years (case n=21, control n=64)	0.70 (0.24, 2.10)	30% (-110, 76)	0.5
≥ 5 years (case n=60, control n=174)	0.37 (0.19, 0.70)	63% (30, 81)	0.002
Stratified by time since vaccination campaign			
≤ 365 days (case n=45, control n=135)	0.30 (0.14, 0.64)	70% (36, 86)	0.002
> 365 days (case n=36, control n=103)	0.75 (0.33, 1.70)	25% (-70, 67)	0.5


435 FIGURES

0 Coverage and Sureveillance Study surveillance facility UHP Boundaries 0 5 10 20 30 40 Kilometers Vaccine campaign community Delayed campaign community

436 Figure 1. Map of vaccine campaign and delayed campaign communities

- 438
- 439
- 440
- 441

442 Figure 2. Trial Profile



453 **FIGURE LEGENDS**

- 454 **Figure 1.** Map of vaccine campaign communities (blue stripes) and delayed campaign communities
- 455 (yellow solid) as demarcated by the borders of Navi Mumbai Municipal Corporation's 22 Urban Health
- 456 Posts. Hospitals that participated in healthcare facility blood culture surveillance marked by green
- 457 circles.
- 458
- 459 **Figure 2**. Flow diagram depicting total estimated eligible participant population in Navi Mumbai
- 460 (~320,000), number of participants reported by healthcare facility blood culture surveillance (4,602),
- 461 number of participants with complete records (2,953), number of participants included in analysis after
- 462 matching (319), and blood culture positive and negatives included in analysis.

463

464